<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384487</url>
  </required_header>
  <id_info>
    <org_study_id>Nidek RS3000-1</org_study_id>
    <nct_id>NCT01384487</nct_id>
  </id_info>
  <brief_title>Nidek RS3000 Comparative Study</brief_title>
  <official_title>Comparative Study of the Nidek Optical Coherence Tomography RS-3000 and the RTVue OCT Predicate Device for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, Pachymetry, Anterior Chamber Imaging and SLO Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nidek Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nidek Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to compare the Nidek RS-3000 Optical
      Coherence Tomography (OCT) device to the Optovue RTVue OCT. The secondary objective is to
      evaluate any adverse events found during the clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Retinal Thickness</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inner Retinal Thickness</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Outer Retinal Thickness</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RNFL Thickness</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optic Disc Analysis</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>G Chart</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Chamber Angle Image</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SLO Image</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pachymetry</measure>
    <time_frame>One Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any adverse events</measure>
    <time_frame>One Visit</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Glaucoma</condition>
  <condition>Retinal Disease</condition>
  <condition>Corneal Disease</condition>
  <arm_group>
    <arm_group_label>Normal Eyes</arm_group_label>
    <description>Eyes without disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes with Glaucoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes with Retinal Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes with Corneal Disease</arm_group_label>
    <description>Including post keratorefractive surgery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of legal age and who have full legal capacity to volunteer on the date the
             informed consent is signed.

          2. Subjects who follow the instructions by Principal/Clinical Investigator or clinical
             staff at the clinical site, and can visit on a scheduled examination date.

          3. Subjects who sign an informed consent form to participate in the clinical study.

          4. Subjects who agree to take the qualifying examination and RS-3000 and RTVue data
             acquisition.

        Exclusion Criteria:

          1. Diabetes mellitus (DM) and/or diabetic retinopathy

          2. Hypertension (HT)

          3. Cerebral infarction, cerebral hemorrhage, cranial nerve neoplasm and other central
             nervous system diseases affecting vision

          4. Cardiac, hepatic, renal and hematologic diseases

          5. Current systemic administration of steroid

          6. History of anticancer agent etc.

          7. Optically-stimulated epileptic seizure

          8. Dementia

          9. Subjects who have other life threatening and debilitating systemic diseases

        NOTE: Additional detailed inclusion/exclusion ophthalmic criteria dependent upon study
        population also exist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Weinreb, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD, Hamilton Glaucoma Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Glaucoma Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viewing and axial cross sectional imaging of ocular</keyword>
  <keyword>structures, including the anterior chamber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

